| Similar Articles |
|---|
 |
The Motley Fool
February 7, 2008
Brian Orelli |
A Lab Match Made in Heaven The case of Thermo Electron and Fisher Scientific shows why mergers work.   |
The Motley Fool
October 26, 2011
Tim Beyers |
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Fishing for Value at Fisher Even with today's earnings-induced jump, there still might be some value here at researcher Fisher Scientific. Investors, take note. |
The Motley Fool
October 24, 2008
Brian Orelli |
Lilly's Results Run the Gamut The company's GAAP EPS and adjusted EPS are at polar extremes. |
The Motley Fool
February 4, 2009
Brian Orelli |
43% Growth! Yee-Haw! Illumina rocks another quarter. |
The Motley Fool
October 26, 2007
Brian Orelli |
This Just In: Mergers Do Indeed Lower Costs As the anniversary integration between Thermo Electron and Fisher Scientific approaches next week, Thermo Fisher Scientific announced third-quarter results that demonstrated how the integration is having a nice effect on the bottom line. |
The Motley Fool
May 8, 2006
Stephen D. Simpson |
Fisher Scientific Reels In a Deal A fair price and impressive market leverage give this merger between Fisher Scientific and Thermo Electron a better-than-average chance. Shareholders, take note. |
The Motley Fool
August 3, 2010
Rex Moore |
The 15 Best Values in Pharma and Biotech Low multiples plus low risk equals compelling value. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
October 26, 2010
Brian Orelli |
Where's the Growth in Big Pharma? The theme for the pharmaceutical industry's 2010 third-quarter earnings reports has been officially set: If you can't get it done through sales, just cut costs. |
The Motley Fool
January 28, 2011
Brian Orelli |
Avoid This Falling Knife for Now 2011 could be just the start of a long slide for Lilly. And 2012 will see difficult year-over-year comparison. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
October 23, 2009
Brian Orelli |
I Don't Need No Massive Merger Plavix's patent expiration is approaching, but Bristol-Myers Squibb is prepared. |
The Motley Fool
May 26, 2011
Andrew Tonner |
Does Agilent Technologies Deserve a Spot in Your Portfolio? Let's take a look at Agilent Technologies and some of its closest peers. |
The Motley Fool
May 23, 2006
Stephen D. Simpson |
Agilent's Increasing Agility The company's restructuring efforts seem to be paying off. Investors, perhaps it is time to get curious. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
October 22, 2009
Brian Orelli |
Beat Earnings, Stock Down, Rinse and Repeat For the second quarter in a row, Eli Lilly beat expectations, it raised guidance, and its stock fell for the day. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
August 16, 2007
Brian Orelli |
More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too. |
Chemistry World
May 10, 2006
Katharine Sanderson |
Leading Lab Suppliers Merge Analytical instrument firm Thermo Electron and chemical manufacturer Fisher Scientific announced a merger, aiming to become the leading provider of laboratory products and services in the health sciences industry. |
The Motley Fool
January 5, 2004
Alyce Lomax |
Side Effects at Lilly? Growing profits, with earnings pains. |
The Motley Fool
April 22, 2008
Brian Lawler |
Lilly in Full Financial Bloom Pharmaceutical Eli Lilly boosts revenue in the first quarter, but its drug-pipeline progress falls short of spectacular. |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably. |
The Motley Fool
July 21, 2011
Seth Jayson |
Why the Future Looks Bright for Thermo Fisher Scientific Although Thermo Fisher Scientific shows inventory growth that outpaces revenue growth, the company may also display positive inventory divergence, suggesting that management sees increased demand on the horizon. |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
Chemistry World
July 8, 2015
Phillip Broadwith |
Thermo Fisher to buy Alfa Aesar chemical supplies The acquisition complements its existing Fisher Scientific chemicals supply segment, and will be integrated with its laboratory products and services portfolio. |
The Motley Fool
January 16, 2009
Brian Orelli |
Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats. |
The Motley Fool
August 11, 2011
Seth Jayson |
1 Reason Waters Corp. May Be Headed for a Slowdown On a sequential-quarter basis, finished goods inventory was also the fastest-growing segment, up 10.3%. That's another warning sign. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
ifeminists
December 28, 2005
Tony Zizza |
If Depression Hurts, Eli Lilly Is Killing Us Eli Lilly's latest marketing campaign is a form of propaganda that speaks to how low Big Pharma will go to keep Americans in chemical handcuffs. |
The Motley Fool
August 24, 2011
Andrew Tonner |
Does Bristol-Myers Squibb Look Like a Winning Investment? Bristol-Myers, Pfizer, and J&J all look tempting, trading in the mid-teens relative to their earnings. |
The Motley Fool
July 23, 2010
Brian Orelli |
Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future? |
CIO
July 27, 2012
Kim S. Nash |
How Thermo Fisher Mines Customer Feedback to Improve Service Thermo Fisher Scientific overhauled its customer feedback system to allow it to be more responsive to current customers and to take advantage of emerging markets |
Chemistry World
April 19, 2013
Sarah Houlton |
Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis. |
